Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. It also sells metered dose inhalers and aerosol sublingual sprays. Through Harvest Medicine, it provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.


TSX:LABS - Post by User

Comment by QContinuum1on Mar 16, 2024 9:24am
75 Views
Post# 35936421

RE:RE:RE:RE:RE:RE:mdjbrown...agree, be it today or 30 years ago on a posting

RE:RE:RE:RE:RE:RE:mdjbrown...agree, be it today or 30 years ago on a posting I never claimed that LABS was not working with a firm or firms that are themselves working on NDA or 505B2 submissions.  What I claim is that those firms can be working on the efforts without making submissions and thus LABS can claim they are working with companies that themselves are supporting those efforts.

Marketing isn't a tough concept but it is clearly lost on some.  LABS has never publicly stated that a full NDA or 505B2 submission was made by a partner.  On materiality alone that would be the minimum required.  Naturally they wouldn't have to get specific on who or even what (as with the ANDA submission to protect confidentiality especially given the ongoing litigation), but given that litigation isn't likely for the NDA or 505B2 submission, one could wonder, what is stopping LABS from making a statement about those efforts in a NR like the ANDA.

Since they haven't made one means it hasn't happened.  Marketing materials are NOT press releases.



<< Previous
Bullboard Posts
Next >>